Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.36 USD | +0.35% | -6.81% | -9.68% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.68% | 4.77B | |
-1.35% | 41.35B | |
+41.82% | 40.38B | |
+3.52% | 39.05B | |
-12.11% | 26.67B | |
+2.03% | 24.07B | |
-23.58% | 18.36B | |
-3.19% | 11.68B | |
+21.20% | 11.6B | |
+7.76% | 11.15B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Piper Sandler Adjusts Price Target on CRISPR Therapeutics to $180 From $107, Reiterates Overweight Rating